DCT and cancer: In another study, Zhang and colleagues demonstrated that fusion of HSC70-derived ATPase domain with tyrosinase-related protein 2 (TRP2) mounted CTL response in B16 melanoma, suggesting that HSC70-based immunotherapy approaches might prove effective for anti-cancer treatment (105, 110).